Plus   Neg

Grifols To Begin Clinical Trial To Evaluate Plasma-derived COVID-19 Drug - Quick Facts

Grifols (GRFS), a global healthcare company, said it will begin a clinical trial in Spain to evaluate the safety and efficacy of a new COVID-19 drug based on immunoglobulin Gamunex-C and containing anti-SARS-CoV-2 polyclonal antibodies from plasma donors. The company expects the trial to begin in February 2021, with the possibility of results in the spring. About 800 patients, tested positive for the virus in a diagnostic test, will participate in the clinical study.

Grifols said the medicine, given subcutaneously, would provide immediate protection after exposure to the virus and could be used to protect the elderly and healthcare workers.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Inter-American Development Bank and Citi Innovation Labs have successfully completed a proof-of-concept to make cross-border payments from the U.S. to countries in Latin America and the Caribbean, using blockchain and tokenized money. The platform provided full traceability of the transactions, exchange rates, and fees on blockchain. Australian competition regulator said the country's Federal Court found that Google and its Australian arm misled users about the collection and use of personal location data. The data was collected through Android mobile devices between January 2017 and December 2018. This is said to be the world-first enforcement action brought by the Australian Competition and Consumer Commission or ACCC. Morgan Stanley (MS) reported a first-quarter profit that more than doubled from last year, reflecting strong performance across all of its business segment. Net revenues for the quarter grew 61 percent from the previous year. Quarterly adjusted earnings per share beat analysts' estimates.
Follow RTT